Resource Logo

Serosurveillance programme evaluated for HIV-1 variation in Europe, Africa and the Caribbean.


Int Conf AIDS. 1993 Jun 6-11;9(1):165 (abstract no. PO-A11-0181). Unique

OBJECTIVE: To obtain insight into the variation of the HIV-1 V3 neutralization domain, necessary for the rational design of subunit) vaccines comprising this domain. METHODS: A serosurveillance programme was developed in which V3 variation of circulating viruses was measured by serological screening of serum samples using a highly discriminatory V3 synthetic peptide 16-17 as residues, ref: Zwart, at al. AIDS Res Hum Retrov, 1992, 8, 11:1897-1908) ELISA and subsequent comparison of V3 peptide antibody reactivity to sequences of viral V3 RNA obtained from the same sera. As sequences of 15 V3 peptides were derived from natural V3 variants circulating in Europe and Africa. RESULTS & CONCLUSION: 60% of 50 Dutch sera, geographically distributed over The Netherlands, showed peak reactivity to p108, p109 and p110 V3MN, differing only at aa 313). 40% reacted with p108 especially. 68% of 70 Curacao samples had peak reactivity to these peptides also, especially to p110 (40%). Peak reactivity to p168 (Tanzanian V3 sequence with a GPGQ central part) was found in 12% of Dutch sera. None of the Curacao samples had peak reactivity to this or any of the other African V3 peptides. 50% of the 51 Tanzanian samples showed peak reactivity to p168, p169 or p170 (V3 sequences obtained from these Tanzanian samples with a GPGQ central part). Reactivity was almost equally distributed among these peptides. 21% of the Tanzanian samples reacted with p164 (Tanzanian V3, GPGR central part). V3 sequences, obtained from viral genomic RNA showed a greater diversity among Tanzanian samples than among Dutch samples. 50% of Tanzanian sequences showed the GPGQ stretch central in the V3 domain. Also a greater variation in length of the V3 region was found among Tanzanian sequences compared to Dutch sequences. In conclusion we found a relative high homogeneity for HIV-1 V3 in Europe and the Caribbean, whereas the diversity at the antigenic and genetic level was relatively high among African HIV-1 variants.



Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.